The Daily Biotech Pulse: AstraZeneca's vaccine as effective as mRNA shots, Humanigen's Lenzilumab disappoints
The Daily Biotech Pulse: AstraZeneca's vaccine as effective as mRNA shots, Humanigen's Lenzilumab disappoints
生物技術每日脈搏：阿斯利康疫苗與mRNA注射一樣有效，Humanigen的lenzilumab令人失望
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述：
Stocks In Focus
關注的股票
Atara Shares Fall After Update On Multiple Sclerosis Trial
Atara股價在多發性硬化症試驗更新後下跌
Atara Biotherapeutics(ATRA.US) completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients.
Atara BioTreateutics(ATRA.US)完成了進展性多發性硬化症患者ATA188第二階段研究(EMBOLD)的中期分析計劃。
The analysis' primary focus was on expanded disability status scale (EDSS) improvement at six months and overall safety.
分析的主要焦點是擴展的殘疾狀況量表(EDSS)在6個月時的改善情況和總體安全性。
The safety monitoring committee believes the six-month interim endpoint may be an inaccurate measure. It recommended continuing the study without sample size adjustment until the final analysis.
安全監測委員會認為，6個月的臨時終點可能是一個不準確的衡量標準。它建議繼續進行這項研究，不調整樣本量，直到最終分析。
The final read-out is planned for October...
最終讀數計劃在2...
登入免費觀看全文
登入/註冊